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Abstract. Vasodepressor (vasovagal) syncope, the 
most common cause of acute loss of consciousness, 
can occur in otherwise vigorously healthy people 
during exposure to stimuli decreasing cardiac filling. 
Antecedent physiological or neuroendocrine condi­
tions for this dramatic syndrome are poorly under­
stood. This study compared neurocirculatory 
responses to non-hypotensive lower body negative 
pressure (LBNP) in subjects who subsequently devel­
oped vasodepressor reactions during hypotensive 
LBNP with responses in subjects who did not. In 
26 healthy subjects, LBNP at —15 and —40 mmHg 
was applied to inhibit cardiopulmonary and arterial 
baroreceptors. All the subjects tolerated 30 min of 
LBNP at —15 mmHg, but during subsequent LBNP 
at -4 0  mmHg 11 subjects had vasodepressor reac­
tions, with sudden hypotension, nausea, and dizzi­
ness. In these subjects, arterial plasma adrenaline 
responses to LBNP both at —15 and at —40 mmHg 
exceeded those in subjects who did not experience 
these reactions. In 16 of the 26 subjects, forearm 
noradrenaline spillover was measured; in the eight 
subjects with a vasodepressor reaction, mean forearm 
noradrenaline spillover failed to increase during 
LBNP at —15mmHg (A ^-0*06±(SE M ) 0*04pmol 
m in'1100 mL“ 1), whereas in the eight subjects 
without a vasodepressor reaction, mean forearm 
noradrenaline spillover increased significantly 
(A =  0*31 ±0* 13 pmol m in '1 lOOmL“ 1). Plasma levels 
of /?-endorphin during LBNP at —15 mmHg increased 
in some subjects who subsequently had a vasodepressor 
reaction during LBNP at —40 mmHg. The findings 
suggest that a neuroendocrine pattern including adre- 
nomedullary stimulation, skeletal sympathoinbibition, 
and release of endogenous opioids can precede vasode­
pressor syncope.
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Introduction
Vasodepressor syncope, or fainting, is the most fre­
quent cause of sudden loss of consciousness [1] and 
can occur in otherwise healthy people during exposure 
to emotional stress, heat, prolonged upright posture, 
or pain. The haemodynamic hallmark of vasodepres­
sor reactions is systemic vasodilation [2], especially in 
skeletal muscle [3,4], with or without vagally 
mediated bradycardia. Microneurographic studies 
have shown that precipitously decreased skeletal sym­
pathetic nervous outflow accompanies the vaso­
dilation [5]. Plasma noradrenaline (NA) levels, 
measured immediately after or at the time of fainting, 
are decreased or inappropriately normal [6,7] and 
release of NA into the venous drainage in the heart 
[8] and kidneys [9] decreases virtually to zero. In 
contrast, plasma adrenaline (A) levels often are 
increased [6]. Vagal bradycardia does riot cause vaso­
depressor reactions, because parasympatholytic drugs 
may not reverse or prevent the hypotension [10].
Mechanisms responsible for the abrupt decreases in 
sympathetic outflows have been unclear. One possi­
bility is sudden central resetting of baroreflexes, so 
that hypotension fails to release sympathoneurai out­
flows from baroreceptor restraint. Since endogenous 
opioids augment the extent of sympathoinhibition 
during a hypotensive stimulus (e.g. haemorrhage 
[11], sudden release of endogenous opioids in the 
brain could contribute to baroreflex resetting and 
thereby produce sympathoinhibition despite hypoten­
sion. Vasopressin also augments baroreflex restraint 
of sympathoneurai outflows [12], and extremely high 
circulating vasopressin levels often accompany vaso­
depressor syncope [13]. Alternatively, stimulation of 
ventricular stretch receptors that increase activity of 
non-myelinated, inhibitory afferent C-fibres [14,15], 
or collapse-firing of low pressure baroreceptors in the 
right atrium and great veins [16], evoke vasodepressor 
reactions. The common feature of the central and 
peripheral hypothesized mechanisms is sympatho­
inhibition despite hypotension.
The suddenness and unexpectedness of vaso­
depressor reactions have hampered efforts to identify
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antecedent haemodynamic and neurohumoral events. 
Prolonged head-up tilt, with or without intravenous 
isoproterenol infusion [17], or relatively large 
amounts of lower body negative pressure (LBNP) 
[18] can provoke these episodes. In the current 
study, we examined circulatory, catecholaminergic, 
and /2-endorphin responses to a small decrease in 
cardiac filling during mild LBNP (-15 mmHg) and 
to systemic hypotension during subsequent more 
intense LBNP (—40 mmHg) in healthy people. 
LBNP at less than -20  mmHg reduces central 
venous pressure without altering arterial blood pres- 
sure or pulse pressure, suggesting relatively selective 
inhibition of cardiac baroreceptors [19], whereas 
higher intensity LBNP decreases blood pressure and 
pulse pressure, inhibiting cardiac and arterial baror­
eceptors. We compared responses in groups of sub­
jects who did, vs. those who did not, develop a 
vasodepressor reaction during high-intensity LBNP, 
in order to identify possible neurochemical antece­
dents of vasodepressor syncope.
To assess neurohumoral responses during inhibi­
tion of cardiopulmonary and arterial baroreceptors, 
plasma catecholamine concentrations were measured. 
Plasma NA levels, however, have some limitations as 
a measure of sympathetic activity since they are the 
net result of the rate by which NA spills over into the 
circulation (after neuronal release and neuronal 
uptake) and the rate by which NA is removed from 
the plasma. Therefore we used the radiotracer dilution 
technique [20] that enables calculation of the total 
body spillover of NA into the circulation. This is a 
better, although not ideal, measure of total body 
neuronal NA release and thus over-all sympathetic 
activity. Since in many conditions sympathetic out­
flow is not uniformly distributed to different organs, 
calculation of the regional spillover of NA in an organ 
is preferred as a measure of regional sympathetic 
activity. Forearm spillover and removal of NA can 
be calculated by measuring forearm blood flow, 
venous and arterial plasma NA levels and the extrac­
tion of the tracer tritiated NA. Measurement of NA  
spillover and removal in the forearm enables to 
identify whether increments in venous forearm 
plasma NA levels are due to an increased neuronal 




Twenty-six healthy male subjects participated in the 
study after giving their written informed consent. The 
study protocol was approved by the Hospital Ethics 
Committee. Before entry into the study, all partici­
pants had a normal physical examination. None 
suifered from cardiovascular or other major diseases, 
and they took no medication. None of the partici­
pants had a history of syncopal attacks.
Study protocol
All subjects abstained from nicotine, alcohol and 
caffeinated foods and beverages for at least 24 h 
before the study. The subjects were allowed to eat a 
light breakfast 2h before the study. All experiments 
were carried out in the morning in a temperature- 
controlled observation room.
During the study, the subjects remained supine, 
with the lower body sealed at the iliac crests in an 
airtight Plexiglas™ box. The applied LBNP pressure 
was recorded by a manometer connected to the inside 
of the box.
After local anaesthesia using lignocaine, a cannula 
was inserted percutaneously into a brachial artery, for 
monitoring arterial blood pressure and heart rate 
(Hewlett Packard GmbH, Böblingen, Germany) and 
for drawing arterial blood samples. In the same arm, a 
cannula was inserted for collecting venous blood.
In 16 of the 26 subjects, another venous cannula 
was inserted in the contralateral arm, for infusion of 
[3H]-noradrenaline ([3H]-NA).
Forearm blood flow (FBF) was measured using 
venous occlusion strain-gauge plethysmography [21]. 
The forearm contralateral to that used for [3H]-NA 
infusion was positioned 10 cm above the mid-thoracic 
level. Measurements of FBF and blood samples were 
obtained after exclusion of the hand circulation by 
inflating a wrist cuff to 100 mmHg above systolic 
blood pressure for at least 1 min [22].
After instrumentation, the subjects rested for at 
least 30 min. During the last 3 min, baseline recordings 
of blood pressure, heart rate, and FBF (nine flow 
curves) were obtained. Blood pressure was recorded 
simultaneously with each FBF measurement. There­
after, arterial and venous blood samples were drawn 
simultaneously for determinations of plasma catecho­
lamines.
LBNP at —15 mmHg was then applied for 30 min. 
Blood pressure, heart rate, FBF recordings and blood 
samples were taken in sequence beginning after 7, 17 
and 27 min of LBNP, so that the blood samples were 
drawn at 10, 20 and 30 min of LBNP. A 30 min rest 
period ensued, followed by another 30 min of LBNP 
—40 mmHg. Blood pressure, pulse rate, FBF, and 
blood samples were obtained at the same time 
points as for LBNP — 15 mmHg.
[SH]-NA infusion
[3H]-NA (levo-[ring-2,556-3H]-NA) was infused to 
assess plasma noradrenaline kinetics. Tritiated NA 
was obtained from Du Pont New England Nuclear 
(’s-Hertogenbosch, the Netherlands). The radionu­
clide was sterilized using a 0-22 ¿¿m filter and diluted 
in 0*9% NaCl containing acetic (O^molL“”1) and 
ascorbic (1 mgmL"1) acid. Aliquots of 50/¿Ci[3H]- 
NA were stored at -80°C  until used. Sterilization, 
dilution and aliquoting were carried out under nitro­
gen. Just before use, an aliquot was diluted in 0*9% 
NaCl. The radiotracer was administered intravenously
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as a bolus of 15¿iCim~2 followed by a constant 
infusion of 0-35 ¿¿Ci min-1 m*“2 for 120min. The first 
LBNP application began at 30 min of infusion of [3H]- 
NA. The weight of the syringe containing the radio­
tracer was measured just before and just after the 
infusion, in order to check the infusion rate. Samples 
of the infusate were taken at the end of the infusion.
Analytical methods
Blood samples were collected in chilled tubes contain­
ing gluthatione (0-2 mol L"1) and EGTA (0-25 
molL”1). The tubes were centrifuged at 4°C and the 
plasma separated and stored at —20°C. Assays of all 
samples and infusâtes occurred within 2 months of 
each study.
Plasma samples were assayed for concentrations of 
adrenaline (A), total NA, and [3H]-NA, using high- 
performance liquid chromatography (HPLC) with 
fluorimetrie detection after precolumn derivatization 
with the fluorescent agent 1,2-diphenylethylenedia- 
mine [23J. A fraction collector connected to an auto­
matic sample injector (WISP 710B, Waters-Millipore, 
Milford, MA, USA), was used for collecting [3H]-NA 
into scintillation vials, according to the retention time 
of NA standard.
Arterial plasma immunoreactive /3-endorphin levels 
were measured by a radioimmunoassay [24] in the 16 
subjects in whom plasma noradrenaline kinetics were 
studied.
Data analysis
Forearm vascular resistance (FVR) was calculated by 
dividing mean arterial blood pressure by FBF and was 
expressed in resistance units (RU). The clearance of 
NA from arterial plasma, CL, was calculated from 
the infusion rate of [3H]-NA and the steady-state 
arterial plasma concentration of [3H]-NA, [3H]-NAa:
CL (Lmin"“1) = Infusion rate (dpmmin-1)/
[3H]-NAa (dpmL-1) (1)
‘Total body’ NA spillover, TB Spill, the estimated 
rate of appearance of endogenous NA in arterial 
plasma, was calculated from the arterial plasma NA  
concentration (NAa) and the arterial steady-state 
clearance of NA, according to the equation:
TB spill (nmol min“ 1) ~  NAa (nmolL"1)
X  CL (Lmin~l) (2)
Analogously, NA spillover in the forearm, FA Spill, 
was estimated from:
FA spill (pmol min"1 lOOmL-' 1) = {FPF x 
NAa x fNA } + (FPF x (NAV -  NAa )} (3)
where fNA = ([3H]-NAa -  [3H]-NAV )/[3H]-NAa, the
fractional extraction of the tracer in the forearm; FPF 
is the forearm plasma flow, in units of mLmin"1 
100 mL*“1, calculated from the forearm blood flow
and haematocrit; and [ H]-NAV is the venous plasma 
concentration of [3H]-NA.
The removal of NA in the forearm, FA Rem, was 
calculated from:
FA Rem (pmol min” 1100 mL"1)
= FPF x NAa x fNA (4)
Subjects were classified post hoc into two groups. 
Subjects in group A underwent both 30 min periods 
of LBNP without experiencing dizziness, nausea, 
weakness or hypotension. Subjects in group B under­
went LBNP at —15 mmHg without symptoms but 
developed a vasodepressor reaction during LBNP at 
—40 mmHg. The criteria for a vasodepressor reaction 
were hypotension (systolic blood pressure < 100 mmHg 
or a rapid decrease of >20 mmHg) and symptoms 
(nausea, dizziness, or weakness).
Results are expressed as means ±  SEM. For each 
LBNP period, values for all dependent variables were 
averaged across the three time points during LBNP. 
To assess the effects of LBNP, the Wilcoxon signed 
rank test was used to compare the baseline with the 
average value of a variable during LBNP. Responses 
at each time point were expressed as the absolute 
change at a time point from the baseline value, and 
two-way analyses of variance ( a n o v a ’ s ) for repeated 
measures were used to compare the changes as a 
function of time in the two groups. A P value less 
then 0*05 defined statistical significance.
Results
Of the 26 subjects, 1.5 (group A) underwent 30 min of 
LBNP at — 15 mmHg as well as at —40 mmHg without 
any signs of a vasodepressor reaction. The remaining
11 subjects (group B) developed a vasodepressor 
reaction during LBNP at —40 mmHg. There were no 
differences in age, resting blood pressure, or heart rate 
between the two groups (Table 1).
All but one subject in group B had both hypoten­
sion and bradycardia during LBNP at —40 mmHg, 
bradycardia being defined as a pulse rate less than 
50 bpm or a rapid decrease of more than 10 bpm. In
Table 1. Clinical characteristics of group A (without syncope) and
group B (with syncope)
Parameter Group A Group B
Number (/?) 15 11
Age (years) 30 ± 5 29 ±6
Height (cm) 184 ±8 184 ±9
Weight (kg) 82-0 ± 10-6 81*7± 10*3
Quetelet index (kgm-2) 24-4 ±3*2 24-2 ±3-6
SBP (mmHg) 120 ± 9 125 ±10
DBP (mmHg) 72 ±8 73 ±9
HR (bpm) 70 ±10 67 ±7
Mean ±  SD are given. The data in this table show blood pressure 
and heart rate values obtained at the screening visit prior to entiy in 
the study. SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HR, heart rate.
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Table 2. Haemodynamic data during LBNP at —15 mmHg in group A (without
syncope, n =  15) and group B (with syncope, « — 11)
Group A Group B
FBF Baseline 1*61 ±0-19 1-46±0'19
(mLmin^1100 mL-'1) LBNP-15 H6±0*15** l-06±0-15**
FVR Baseline 64 ± 8 71 ±  10
(resistance units) LBNP-15 90±  10** 99±13**
SBP Baseline 126 ±  4 128 ± 4
(mmHg) LBNP-15 127 ± 3 130 ± 4
DBP Baseline 73 ± 3 67 ± 2
(mmHg) LBNP-15 75 ± 3 69 ±  3
Pulse pressure Baseline 61 ± 2 64 ± 2
(mmHg) LBNP-15 59 ± 2 61 ± 2
Heart rate Baseline 5 5 ± 3 59 ± 2
(bpm) LBNP-15 54 i  3 60 ± 2
M eaniSEM  are given. SBP, systolic blood pressure; DBP, diastolic blood 
pressure; FBF, forearm blood flow; FVR; forearm vasular resistance. 
** P < 0-01 with respect to baseline.
group B subjects, LBNP at -40  mmHg was 
terminated immediately when the first signs of a 
vasodepressor reaction emerged. All group B subjects 
complained of nausea, and some became pale; one lost 
consciousness. The vasodepressor response occurred 
in the first 10 min of LBNP at -40  mmHg in two 
subjects, between 10 and 20 min in seven subjects, and 
in the last 10 min in two subjects. Consequently > the 
data summarized below for LBNP at -40  mmHg are 
incomplete for group B.
LBNP at —15 mmHg
During LBNP at -15  mmHg, FBF decreased and 
FVR increased significantly in both groups (Table 2), 
and the groups did not differ in values for these 
variables. Blood pressure, pulse pressure, and heart 
rate did not change during LBNP at -15 mmHg in 
either group.
Baseline levels of venous plasma NA were similar in 
the two groups (0*92 ±  0*10 nmol L_1 in group A and 
L00 ±0*09 nmol L^1 in group B). During LBNP, 
venous plasma NA levels increased significantly in 
both groups to 1 *38 ±0*13 nmol L-1 in group A and 
1-26 ±0*11 nmolL"1 in group B at 30 min of LBNP. 
There was a tendency for smaller venous plasma NA 
responses in the group with subsequent syncope but 
the increments in venous NA levels were not signifi­
cantly different between the two goups (Fig. 1).
Baseline arterial plasma NA levels also did not differ 
between the groups. Arterial NA levels increased from 
0*94 ± 0-08 to a maximal value of 1 * 10 ±  0*08 nmol L“ 1 
in group A and from 0 * 92 ±  0 ■ 11 nmol L"1 
1 *03 ± 0*09 nmol L'1 in group B.
Baseline arterial A levels were similar in the two 
groups (0* 16 ±0*03 nmol L”-1 in group 
0*17 ±0*03 nmol L"1 in group B). In both groups, 




at -1 5  mmHg; however, in group A, arterial A levels 
plateaued at about 0-22 nmol L_1 after 10 min, 
whereas in group B, arterial A levels progressively 
rose to a peak value of 0*34 ±  0*05 nmol L^1. Thus, the 
absolute increments in arterial A levels were larger in 
the group with than in the group without subsequent 
syncope (Fig. 2). Venous plasma A responses did not 
differ between the two groups.
In the 16 subjects who received a [3H]-NA infusion, 
mean FA Spill at baseline was not significantly differ­
ent between group A (n =  8) and group B (n =  81 
subjects (0*63 ±0-16 vs. 0*76 ±0*16 pmol min 
100 mL"*1, Table 3). During LBNP at —15 mmHg, 
the average response of FA Spill across all time 
points was larger in the group A subjects 
(0*31 ±0*13 pmol min”1100 mL”1) than in the 
group B subjects (-0*06 ±0*04 pmol min“'1100 mL”1, 
P  < 0 *05, Fig. 3).
Values for TB Spill did not change significantly in 
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10 min 20 min 30 min
Figure 1. Increments in venous plasma noradrenaline (NÀ, means 
±  SEM) after 10, 20 and 30 min oflower body negative pressure for 
group A (n =  15, no syncope) and group B (n =  11, syncope).
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p<0*05 No syncope v s. syncope (two-way anova)
Figure 2. Increments ín arteriai plasma adrenaline (A, means 
±SEM) after 10, 20 and 30min of lower body negative pressure 
for group A (n =  1.5, no syncope) and group B (n =  11, syncope).
Values for CL decreased by about 30% in group A 
and did not change in group B. In neither group did 
values for FA Rem change during LBNP at 
— 15 mmHg.
Baseline plasma /3-endorphin levels did not differ 
between the groups and did not change significantly 
during LBNP at -1 5  mmHg in group A 
(27±3pgm L“1 at baseline to 30±4pgm L "1 during 
LBNP). In group B, plasma /3-endorphin increased in 
three of the eight subjects; the average increase, from 
3 8 ± llp g m L _1 at baseline to 62±28pgm L ~T 
during LBNP at -1 5  mmHg, was not significant.
LBNP at —40 mmHg
In both group A and group B, FBF decreased and 
FVR increased during LBNP at —40 mmHg, analo­
gous to the changes during LBNP at —15 mmHg 
(Table 4); however, the changes in values for both
variables were larger during LBNP at -40 mmHg 
than during LBNP at -1 5  mmHg. Systolic blood 
pressure and pulse pressure decreased and heart rate 
increased, both in the group A subjects and in the nine 
group B subjects.
Baseline levels of venous plasma NA were similar in 
the two groups (1-08 ±0*13 nmol L '1 in group A and 
M 0± 0T 2n m olL _1 in group B). During LBNP, 
venous plasma NA levels increased significantly in 
both groups to 2* 12 ±0-22 nmol L“1 in group A and 
2*11 ±0'22nm olL-1 in group B.
In the group A subjects, arterial plasma NA 
increased from 1*01 ±0-10 to 1-76 ±0*09 nmol L”1 
(P < 0*01). In the nine group B subjects, the arter­
ial plasma NA response (from 0-93 ±0-10 to 
l*50±0'14nmolL_1, P < 0 - 0 1 )  after 10min of 
LBNP at —40 mmHg did not differ significantly 
from that in the group A subjects.
Arterial plasma A levels increased in the group 
A subjects from 0*21 ±0*02 nmol L~] to 
0*39 ±0*04 nmol L-1 (P<0-01)  during LBNP at 
-4 0  mmHg and increased markedly in the nine 
group B subjects from 0*30 ± 0 ’04 nmol L”1 to 
l*24± 0 ,44nmolL“1 (P<0*01) after 10min of 
LBNP.
In group A total body NA spillover increased 
significantly by about 30% during LBNP at 
—40 mmHg, and NA clearance decreased significantly 
by about 40% (Table 5); in group B, total body NA 
spillover increased in five subjects, but this response 
was not significant (Table 5). Forearm NA spillover 
increased in the group A subjects, from 0*73 ±  0*19 to 
l'32±0'36pm olm in_1100mL'~1, P<0*05,  whereas 
in group B there was no significant change (Table 5).
Plasma /3-endorphin levels did not change during 
LBNP at -4 0  mmHg in group A (34±6pgmL~1 at 
baseline, 38±5pgmJLTI during LBNP), whereas in 
group B plasma /3-endorphin increased in six of the 
eight subjects; the average increase, from
Table 3. Noradrenaline kinetics values during LBNP at -1 5  mmHg in group A
(without syncope, n — 8) and group B (with syncope, n =  8)
Group A Group B
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1*37 ±  0’ 15
0*99 ±0-16 
1 *26 ±0*16
Total body NA 
clearance 





1*30 ±  0-14 
1*32 ±0*07
MeansdtSEM are given. NA, noradrenaline. *P < 0-05  with respect to 
baseline.
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however, cholinergic blockade may not prevent or 
reverse the hypotension. More recently, microneuro­
graphic [5] and neurochemical [6,7] evidence has 
convincingly demonstrated virtually complete shut­
down of sympathoneurai cardiovascular outflows, 
with generally preserved or augmented adrenomedul- 
lary secretion [25]. This combination could contribute 
to the skeletal vasodilation that virtually always 
accompanies vasodepressor reactions.
Lower body negative pressure at -15  mmHg inhi­
bits cardiac ‘low pressure’ baroreceptors. During 
LBNP at — 15 mmHg, skeletal muscle sympatho­
neurai outflow normally increases reflexively 
[7,26,27]. Exposure to LBNP at -4 0  mmHg inhibits 
cardiac and arterial baroreceptors, increasing sym­
pathoneurai outflow in several vascular beds and 
concurrently increasing adrenomedullary secretion. 
Diffuse reflexive sympathoadrenal stimulation in this 
setting probably supports systemic blood pressure and 
cerebral perfusion.
In the present study, sudden vasodepressor reactions 
occurred in 11 of 26 healthy subjects during prolonged 
exposure to LBNP at —40 mmHg. The study design 
enabled review of cat echo laminergic function before the 
actual vasodepressor reactions, that is during LBNP at 
-1 5  mmHg. The findings indicate that a combination of 
attenuated noradrenergic and exaggerated adrenome­
dullary and possibly endogenous opioid responses to 
mildly decreased cardiac filling (LBNP at — 15 mmHg) 
characterized subjects who subsequently developed 
vasodepressor reactions during exposure to more 
severely decreased cardiac filling (group B). These sub­
jects failed to increase forearm NA spillover during 
exposure to LBNP at —15 mmHg and had enhanced 
increases in arterial A levels.
Table 4. Haemodynamic data during LBNP at -40  mmHg in group A (without
syncope, n =  15) and group B (with syncope, n —9*)
Group A Group B
FBF Baseline 1-49 ±  0-17 1-16 ±0-16
(mLmin”1100 mL“1) LBNP-40 0-88 ±  0’14f 0-65±0-10t
FVR Baseline 71 ± 8 94 ±11
(resistance units) LBNP-40 135±18t L65±21t
SBP Baseline 129 ± 2 140 ± 5
(mmHg) LBNP-40 125 ± 3 t 131 ± 5 t
DBP Baseline 73 ± 3 75 ±  3
(mmHg) LBNP-40 75 ± 3 75 ± 3
Pulse pressure Baseline 57 ± 3 65 ±  3
(mmHg) LBNP-40 5 0 ± 4 f 56± 3f
Heart rate Baseline 54 ± 2 57 ± 2
(bpm) LBNP-40 6 2 ± 3 f 6 8 ± 4 |
Means ±  SEM are given, SBP, systolic blood pressure; DBP, diastolic blood 
pressure; FBF, forearm blood flow; FVR; forearm vasular resistance. * Repre­
sents the data of nine subjects of group B (n =  11) who tolerated the first 10 min 
of LBNP at -40 mmHg but who later developed a vasodepressor reaction. Two 
subjects had a vasodepressor reaction in the first 1 Omin of LBNP at —40 mmHg. 
XP < 0*01, t  < 0-001 with respect to baseline.
P<0*05
No syncope Syncope
Figure 3. Individual responses of forearm noradrenaline (NA) 
spillover in eight subjects without and eight subjects with syncope. 
FAV = forearm volume.
59±12pgm L 1 at baseline to 82±22pgm L 1 
during LBNP at —40 mmHg, was not significant.
Discussion
Few occurrences in clinical medicine match vaso­
depressor reactions for abruptness, unexpectedness 
and drama. The neurocirculatory basis for vaso­
depressor reactions was long presumed to be diffusely 
increased vagal 'tone5, since people experiencing 
them often have nausea, sweating and bradycardia;
©  1995 Blackwell Science Ltd, European Journal o f  Clinical Investigation, 25, 754-761
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Table 5. Noradrenaline kinetics values during LBNP at -4 0  mmHg in group A
(without syncope, n = 8) and group B (with syncope, n =  6*)
Group A Group B
Arterial plasma NA Baseline 1-01 ± 0-12 0*82 ± 0-11
(nmolL“1) LBNP-40 1 *88 d= 0*08J 1 *50 zt 0*211
Forearm NA Baseline 0*73 ±0*19 0-60±0-17
spillover
(pmol min" 1 100 mL”1)
LBNP-40 l-32±0-36t 0*73 ±0*15
Total body NA Baseline 1 *47 ±0-20 1*05 ±0*18
spillover 
(nmol min“ 1 m~2)
LBNP-40 1‘91 ±0*15J 1 *87 ±  0-24
Total body NA Baseline 1*51 ±0*17 1*25 ±0*10
clearance
(L m in^m “2)
LBNP-40 l ’02±0*07t 1 *31 ±  0*20
Means ±  SEM are given. N A, noradrenaline. * Represents the data for six 
subjects of group B (n =  8) who tolerated the first 10 min of LBNP at 
—40 mmHg but who developed a vasodepressor reaction later. Two subjects 
had a vasodepressor reaction in the first 10 min of LBNP at —40 mmHg. 
f i 3 < 0-05 and %P < 0*01 with respect to baseline.
Forearm vasoconstriction occurred in the group B 
subjects during LBNP at —15 mmHg, despite the 
absence of increased forearm NA spillover. The 
basis for the forearm vasoconstriction without con­
currently increased regional NA spillover cannot be 
determined from the present data. Several explana­
tions are possible, including augmented extraneuronal 
removal of NA escaping the neuroeffector junctions, 
release of vasoconstrictor peptides such as NPY or 
ATP, blockade of formation of endothelium-derived 
relaxing factors, or concurrent inhibition of sympa­
thetic cholinergic vasodilation.
It is a possibility that this pattern of sympathoinhi- 
bition and adrenomedullary stimulation reflects a 
central neural process and arises from sudden reset­
ting of baroreflexes. Analogous resetting occurs 
during haemorrhage [28] and hypoglycaemia [29] in 
laboratory animals and produces a neurocirculatory 
positive feedback loop that leads rapidly to hypo­
tension and circulatory shock. Moreover, electrical 
stimulation of specific hypothalamic regions can con­
currently increase vagal and decrease sympathoneurai 
outflows, evoking hypotension [30]. Disruption of 
vagal afferents or blockade of receptors for vaso­
pressin or endogenous opioids can reverse the 
sympathoinhibition attending haemorrhage or hypo­
glycaemia, and it is therefore possible that central 
processes involving these compounds may also oper­
ate in some vasodepressor reactions.
Vasovagal syncope frequently occurs in emotion­
ally distressing circumstances. Individuals who 
developed a vasodepressor reaction had enhanced 
plasma A responses. Exaggerated endogenous A  
responses may also be part of a centrally generated 
pattern that triggers or reinforces a neurocirculatory 
positive feedback loop. Consistent with this view, a 
recent study in a small group of subjects also reported 
increases in plasma A levels before the onset of
fainting and suggested that increased plasma A con­
tributed to the vasodilation [31]. This helps to explain 
why /3-adrenoceptor blockade can be useful in treat­
ing patients with recurrent vasodepressor syncope 
[32,33]. Exogenous administration of A alone does 
not cause syncope in healthy people.
Several investigators have proposed that in volume- 
depleted subjects, cardiac contraction around a near- 
empty ventricle at end-systole can paradoxically 
stimulate inhibitory ventricular myocardial receptors, 
evoking a depressor reflex [14]. This mechanism, 
although widely accepted, has never actually been 
demonstrated as a cause of vasovagal syncope. On 
the contrary, infusion of a vasodilator has been 
reported to evoke vasodepressor syncope in a heart 
transplant recipient who lacked cardiac innervation 
[34], and heart transplant recipients do not differ from 
healthy control subjects in their susceptibility to 
LBNP-induced vasodepression [35]. In cats and rats, 
but not in dogs, interference with cardiac vagal C- 
fibre afferents prevents haemorrhage-induced vasode­
pression [15]. These findings suggest that the occur­
rence of vasodepressor syncope in humans may not 
require altered neuronal afferent input from ventricu­
lar baroreceptors and that the relative contributions 
of peripheral and central mechanisms vary among 
species.
The central aetiology hypothesis has direct thera­
peutic implications, since /9-adrenoceptor blockade, 
administration of an a-adrenoceptor agonist or sym­
pathomimetic amine, blockade of endogenous opiate 
effects, or blockade of vasopressin receptors would be 
expected to abort or prevent vasodepressor syncope. 
The beneficial effects of /3-blockade were noted above 
[32, 33]. Treatment with dextroamphetamine [36], 
pseudoephedrine or phenylephrine [37] appears to 
prevent syncope in patients with positive tilt testing. 
Pre-treatment with naloxone, however, does not
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prevent vasodepressor responses during repeat expo­
sure to LBNP in healthy subjects with previous 
LBNP-induced syncope [38]. We did not find reports 
about effects of vasopressin antagonists.
In summary, healthy subjects who developed vaso­
depressor reactions during high-intensity LBNP had 
antecedent exaggerated adrenomedullary and attenu­
ated sympathoneurai responses during mild LBNP; 
some subjects who developed a vasodepressor reac­
tion during high-intensity LBNP had /3-endorphin 
responses during mild LBNP. The findings are con­
sistent with the view that sudden, central resetting of 
baroreflex function can evoke a pattern of sympatho­
neurai inhibition combined with adrenomedullary 
and vagal activation, producing neurocirculatory 
positive feedback loops that lead precipitously to 
hypotension and syncope.
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